Granda-Cameron C, Behta M, Hovinga M, Rundio A: Risk factors associated with unplanned hospital readmissions in adults with cancer. Oncol Nurs Forum 42 (3): E257-68,2015.
Generalizations of a generalist Journal of Community and Supportive Oncology in press : 2015.
Raess Philipp W, Mintzer David, Husson Michael, Nakashima Megan O, Morrissette Jennifer J D, Daber Robert: BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia. Blood 122 (17): 3084-5,2013.
Oncodoxes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 (3): 393-4,2013.
Dotan Efrat, Meropol Neal J, Burtness Barbara, Denlinger Crystal S, Lee James, Mintzer David, Zhu Fang, Ruth Karen, Tuttle Holly, Sylvester Judi: A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. Journal of gastrointestinal cancer 43 (4): 562-9,2012.
Schwartzberg Lee S, Arena Francis P, Mintzer David M, Epperson Amanda L: Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clinical breast cancer 12 (2): 87-93,2012.
Granda-Cameron Clara, DeMille Debra, Lynch Mary Pat, Huntzinger Christine, Alcorn Theresa, Levicoff Joan, Roop Carly: An interdisciplinary approach to manage cancer cachexia. Clinical journal of oncology nursing 14 (1): 72-80,2010.
Mintzer David M, Zheng Sarah, Nagamine Michiko, Newman Jason: Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital. The oncologist 15 (1): 51-8,2010.
Mintzer David M, Billet Shira N: Drug-induced hematologic syndromes. Advances in hematology 2009 : 495863,2009.
Borghaei Hossein, Langer Corey J, Millenson Michael, Ruth Karen J, Litwin Samuel, Tuttle Holly, Seldomridge Judie Sylvester, Rovito Marc, Mintzer David, Cohen Roger: Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 3 (11): 1286-92,2008.